Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles
Experts caution that realizing AI’s potential requires careful management and risk mitigation
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Heart failure affects an estimated 64.3 million people worldwide
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
Subscribe To Our Newsletter & Stay Updated